Abstract
This statement sets out advice from the JCVI on the benefits of a third primary COVID-19 vaccine dose in individuals aged 12 years and over with severe immunosuppression around the time of their first or second vaccine doses.
- Recommendation
- Europe
- United Kingdom
- immunocompromised
- COVID-19